Clover Biopharmaceuticals, Ltd. (HKG:2197)

Hong Kong · Delayed Price · Currency is HKD

2.000

+0.250 (14.29%)

Jul 31, 2026, 4:08 PM HKT

Clover Biopharmaceuticals Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3.51	3.51	38.42	39.26	-	-
Revenue Growth	-93.23%	-90.88%	-2.13%	-	-	-
Gross Profit	3.31	3.31	-672.94	-1,673	-475.64	-66.27
Operating Income	-254.89	-254.89	-954.84	-2,601	-2,400	-2,239
Net Income	-205.09	-205.09	-903.43	-138.54	-2,452	-6,016
Earnings Per Share	-0.16	-0.16	-0.72	-0.11	-2.22	-5.19
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Mainland China	3.51	3.51	35.18	39.26
Korea	-	-	3.24	-
Total	3.51	3.51	38.42	39.26

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	282.25	282.25	416.02	752.97	1,624	2,859
Total Debt	10.61	10.61	89.64	334.45	354.37	67.92
Net Cash (Debt)	271.64	271.64	326.38	418.52	1,270	2,791
Net Cash Growth	-29.02%	-16.77%	-22.02%	-67.04%	-54.51%	-
Net Cash Per Share	0.22	0.22	0.26	0.34	1.15	2.41

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-194.83	-194.83	-288.49	-727.88	-1,691	-917.75
Capital Expenditures	-0.03	-0.03	-1.13	-6.95	-77.03	-59.25
Free Cash Flow	-194.86	-194.86	-289.62	-734.83	-1,768	-977
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	94.29%	94.29%	-	-	-	-
Operating Margin	-7272.18%	-7272.18%	-2485.33%	-6626.46%	-	-
Pretax Margin	-5851.41%	-5851.41%	-2351.51%	-352.92%	-	-
Profit Margin	-5851.41%	-5851.41%	-2351.51%	-352.92%	-	-
FCF Margin	-5559.46%	-5559.46%	-753.84%	-1871.94%	-	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	-	0.71	0.71	0.78	5.87	5.49
PS Ratio	665.59	778.62	7.65	18.58	-	-